Businesswire·2025-10-29 10:30Core Insights - Compass Pathways plc has appointed Dr. Jeffrey Jonas to its Board of Directors, effective immediately, bringing over 30 years of experience in pharmaceutical research and development, particularly in neuroscience [1][3][4] - Thomas Lönngren will retire from the Board at the end of December after more than six years of service, having contributed significantly to the company's achievements, including the advancement of the COMP360 program [2][3] Company Overview - Compass Pathways is a biotechnology company focused on accelerating patient access to evidence-based innovations in mental health, particularly through its investigational COMP360 synthetic psilocybin treatment [6][7] - The company aims to address the growing mental health crisis by developing transformative treatments for conditions that are not adequately addressed by existing therapies [5][6] Product Development - COMP360 has received Breakthrough Therapy designation from the US FDA and Innovative Licensing and Access Pathway designation in the UK for treatment-resistant depression [7] - The company is pioneering a new treatment paradigm aimed at achieving rapid and durable responses for patients with serious mental health conditions [6][7] Leadership and Expertise - Dr. Jonas has held various leadership roles in life sciences, including CEO of Sage Therapeutics and President of the Regenerative Medicine Division at Shire Pharmaceuticals, and has a strong background in psychiatric disorders and neuropsychopharmacology [3][4] - His extensive experience is expected to be beneficial as Compass Pathways works towards bringing COMP360 to market, pending regulatory approval [3][5]